Catalent continues to scout acquisitions and licensing in 2016

By Natalie Morrison

- Last updated on GMT

Image: iStock/DigtialStorm
Image: iStock/DigtialStorm
Catalent will pursue strategic acquisitions and licensing in 2016, said VP Marketing & Strategy Elliott Berger, noting growth areas include complex delivery technologies and specialised logistics.

The fragmented contract manufacturing and pharma services sectors are being incentivised to accelerate consolidation because of growing client demand for fewer providers, Berger said.

Catalent  has completed several delivery technology-focused acquisitions in recent years, including late-2014 purchases of Micron Technologies​ and Redwood's SMARTag ADC​. The contract development and manufacturing organisation (CDMO) has also been acquisitive in regions such as China and Brazil, Berger added, noting it would be open to further such opportunities.

Technologies which improve solubility and bioavailability of increasingly complex new therapies continue to be of interest for Catalent, Berger added.

Berger did not reveal potential target or deal size, nor give guidance on any warchest the company may have. Catalent's cash and cash equivalents in its most recent quarterly report​ -- released November 2015 -- was $151.4 million.

Meanwhile, demand for more global clinical trials continues to rise, meaning localised logistics capabilities such as cold chain distribution and specialised handling and packaging services are a growth target for Catalent, Berger said.

Asia Pacific in particular is seeing mounting popularity as a trial destination, and as target markets for commercialisation, he said. Earlier this month plans for expansion of the company's cGMP facility in Japan for secondary packaging and clinical supply services was announced.

The Somerset, New Jersey-based firm is also experiencing growing demands for specialty handling services such as scheduled storage, cold chain logistics and handling of potent and cytotoxic compounds as biologics and biosimilars popularity continues, Berger said.

In its most recent annual report​, released in September 2015, Catalent said it will remain opportunistic to acquisitions and referred to its nine acquisitions since fiscal year 2012 totalling more than $700m investment. 

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars